Associated Papers
The impact of single nucleotide polymorphisms on the absorption, distribution, metabolism, and excretion of dietary (poly)phenols: a critical systematic review.
Tosi N et al.
Food & Function, 2025
Impacts of Pharmacokinetic Gene Polymorphisms on Steady-State Plasma Concentrations of Simvastatin in Thai Population.
Tipnoppanon S et al.
Clinical and Translational Science, 2025
Benign inheritable disorders of bilirubin metabolism manifested by conjugated hyperbilirubinemia-A narrative review.
Morais MB et al.
United European Gastroenterology Journal, 2022
Systematic Review of Pharmacogenetic Factors That Influence High-Dose Methotrexate Pharmacokinetics in Pediatric Malignancies.
Taylor ZL et al.
Cancers, 2021
PBPK Model of Coproporphyrin I: Evaluation of the Impact of SLCO1B1 Genotype, Ethnicity, and Sex on its Inter-Individual Variability.
Takita H et al.
Cpt: Pharmacometrics & Systems Pharmacology, 2021
Endogenous Metabolites-Mediated Communication Between OAT1/OAT3 and OATP1B1 May Explain the Association Between SLCO1B1 SNPs and Methotrexate Toxicity.
Martinez D et al.
Clinical Pharmacology and Therapeutics, 2018
Effect of ABCB1 diplotype on tacrolimus disposition in renal recipients depends on CYP3A5 and CYP3A4 genotype.
Vanhove T et al.
The Pharmacogenomics Journal, 2017
The Promise of Pharmacogenomics in Reducing Toxicity During Acute Lymphoblastic Leukemia Maintenance Treatment.
Rudin S et al.
Genomics, Proteomics & Bioinformatics, 2017
Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins.
Arrigoni E et al.
International Journal of Molecular Sciences, 2017
Association of genetic variations with pharmacokinetics and lipid-lowering response to atorvastatin in healthy Korean subjects.
Woo HI et al.
Drug Design, Development and Therapy, 2017
Absence of ethnic differences in the pharmacokinetics of moxifloxacin, simvastatin, and meloxicam among three East Asian populations and Caucasians.
Hasunuma T et al.
British Journal of Clinical Pharmacology, 2016
Genetic and/or non-genetic causes for inter-individual and inter-cellular variability in transporter protein expression: implications for understanding drug efficacy and toxicity.
Koo SH et al.
Expert Opinion on Drug Metabolism & Toxicology, 2015
Pharmacogenetic considerations for acute lymphoblastic leukemia therapies.
Dulucq S et al.
Expert Opinion on Drug Metabolism & Toxicology, 2014
Genetic polymorphisms predicting methotrexate blood levels and toxicity in adult non-Hodgkin lymphoma.
Avivi I et al.
Leukemia & Lymphoma, 2014
Interindividual variability in hepatic organic anion-transporting polypeptides and P-glycoprotein (ABCB1) protein expression: quantification by liquid chromatography tandem mass spectroscopy and influence of genotype, age, and sex.
Prasad B et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2014
Pharmacogenetics of membrane transporters: a review of current approaches.
Sissung TM et al.
Methods in Molecular Biology (clifton, N.j.), 2014
Pharmacogenomics and adverse drug reactions: the case of statins.
Giorgi MA et al.
Expert Opinion on Pharmacotherapy, 2011
Hepatic OATP and OCT uptake transporters: their role for drug-drug interactions and pharmacogenetic aspects.
Fahrmayr C et al.
Drug Metabolism Reviews, 2010
UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients.
Onoue M et al.
International Journal of Clinical Oncology, 2009
Clinical and pharmacogenetic factors associated with irinotecan toxicity.
Kweekel D et al.
Cancer Treatment Reviews, 2008
OATP1B1 polymorphism is a major determinant of serum bilirubin level but not associated with rifampicin-mediated bilirubin elevation.
Zhang W et al.
Clinical and Experimental Pharmacology & Physiology, 2007
Pharmacogenetics of SLCO1B1: haplotypes, htSNPs and hepatic expression in three distinct Asian populations.
Jada SR et al.
European Journal of Clinical Pharmacology, 2007